WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Brendan Steele leads LIV Adelaide by one stroke after second round at The GrangeA former Democratic Georgia congressman hopes abortion can power his state Supreme Court bidThree cheers for the King! Queen Máxima of the Netherlands is a vision in green as King WillemIndiana voters to pick party candidates in competitive, multimillion dollar primariesSZA and Keke Palmer are set to star in a buddy comedy from producer Issa RaeMarcus Rashford cannot be painted as an innocent victim when he is looking like the brash £315kHamas is reviewing an Israeli proposal for a ceaseHelen Skelton reveals the one question she detests being asked by 'mumSchwarber and Harper lead Phillies' power display in 9Hamas is reviewing an Israeli proposal for a cease